MRI + Blood Testing for Brain Tumor

This trial explores whether a special type of MRI scan and blood tests can predict changes in WHO grade IV glioma, an aggressive brain tumor. Participants will undergo these tests while receiving their normal cancer treatments to determine if they can track the tumor's progress. The trial involves a specific MRI scan, T2 (Observed)-Weighted Imaging, and blood samples taken during and after radiation sessions. It seeks individuals over 21 who have recently been diagnosed with this type of brain tumor and can undergo MRIs and provide blood samples. As an unphased trial, it offers a unique opportunity to contribute to groundbreaking research that could enhance future diagnostic methods.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that T2 star (T2*)-weighted MRI reliably detects brain lesions and tracks their spread. Hospitals often use it to obtain clear images of brain tumors, aiding doctors in treatment planning. Studies have reported that this type of MRI is generally well-tolerated, with no significant risks.

Blood tests are a routine part of medical check-ups and are usually safe. Taking blood samples to check for biomarkers, which can indicate disease, is standard practice. This helps doctors predict how a tumor might change over time.

Researchers are excited about this trial because it combines T2*-weighted MRI imaging with blood testing to monitor brain tumors. Unlike standard imaging techniques, this method aims to provide more detailed and dynamic images of the tumor over time, potentially allowing for better monitoring of how the tumor responds to treatment. Additionally, integrating blood sample analysis might offer insights into tumor biology and treatment effectiveness without the need for invasive procedures. This approach could lead to more personalized and timely treatment adjustments, enhancing patient outcomes.

Research has shown that a special type of MRI scan, called T2-weighted MRI, is useful for detecting and understanding brain tumors. Studies indicate that these images help doctors see the edges of a tumor and its impact on nearby brain tissue. This trial will use T2-weighted MRI alongside blood sample collection to evaluate their combined effectiveness in monitoring brain tumors. This technique can highlight areas that appear different, which is crucial for assessing brain tumors. Additionally, using MRI scans with blood tests might help predict tumor changes over time, simplifying disease tracking. Although limited data exists on using this combination in people, it shows promise for improved monitoring of brain tumors.³⁶⁷⁸⁹